Study of the use of vitamin K in neonates in France A. P. Jonville-BeraE. Autret CLINICAL TRIALS Pages: 333 - 337
A comparative study of the effects of yohimbine and anetholtrithione on salivary secretion in depressed patients treated with psychotropic drugs H. BagheriL. SchmittJ. L. Montastruc PHARMACODYNAMICS Pages: 339 - 342
Salt enhances responsiveness of terminal aortic vascular bed to sympathetic activity H. ShimamotoY. Shimamoto PHARMACODYNAMICS Pages: 343 - 349
Moxonidine and cognitive function: interactions with moclobemide and lorazepam K. WesnesP. M. SimpsonH. Küppers PHARMACODYNAMICS Pages: 351 - 358
The negative mucosal potential: separating central and peripheral effects of NSAIDs in man J. LötschT. HummelG. Kobal PHARMACODYNAMICS Pages: 359 - 364
The clinical phcarmacology of single doses of otilonium bromide in healthy volunteers J. A. SuttonS. G. KilminsterG. P. Mould PHARMACODYNAMICS Pages: 365 - 369
Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide M. BindschedlerP. DegenG. Preiswerk PHARMACOKINETICS AND DISPOSITION Pages: 371 - 378
Transdermal nitroglycerin: clinical and pharmacokinetic consequences of renewing the patch and the application site T. O. KlemsdalH. H. MundalK. Gjesdal PHARMACOKINETICS AND DISPOSITION Pages: 379 - 381
Ketotifen pharmacokinetics in children with atopic perennial asthma M. L. McFadyenR. MillerT. M. Ludden PHARMACOKINETICS AND DISPOSITION Pages: 383 - 386
Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? S. V. VormfeldeA. BitschC. H. Gleiter PHARMACOKINETICS AND DISPOSITION Pages: 387 - 390
Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects H. KatsukiC. NakamuraM. Nakano PHARMACOKINETICS AND DISPOSITION Pages: 391 - 396
Comparison of pharmacokinetics and dynamics of two dosage regimens of foscarnet in AIDS patients with Cytomegalovirus retinitis F. CastelliL. TomasoniA. Hedman PHARMACOKINETICS AND DISPOSITION Pages: 397 - 401
Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite E. LukkariA. JuhakoskiP. J. Neuvonen PHARMACOKINETICS AND DISPOSITION Pages: 403 - 406
Pharmacokinetics of cloxacillin in patients undergoing hip or knee replacement E. VingeG. NergeliusL. Lidgren PHARMACOKINETICS AND DISPOSITION Pages: 407 - 411
A comparison of EMIT and FPIA methods for the detection of cyclosporin A blood levels: does impaired liver function make a difference? O. WitzkeU. HeemannM. C. Michel PHARMACOKINETICS AND DISPOSITION Pages: 413 - 416
Dextromethorphan O-demethylation polymorphism in the Uruguayan population F. EstevezM. GiustiJ. Oxandabarat LETTER TO THE EDITORS Pages: 417 - 418
Is there any difference between daytime and nighttime debrisoquine metabolism? R. BordetA. BelabbasC. Libersa LETTER TO THE EDITOR Pages: 419 - 420